期刊
MOLECULAR SYSTEMS BIOLOGY
卷 17, 期 3, 页码 -出版社
WILEY
DOI: 10.15252/msb.20209810
关键词
cancer etiology; driver-gene combinations; multi-gene biomarkers; patient stratification; precision oncology
资金
- National Institutes of Health [P30CA016359, P50CA1965305]
The CRSO method can infer combinations of alterations that cooperate to drive tumor formation in individual patients, identifying driver gene combinations and new synergies that provide novel insights into cancer etiology and personalized treatments.
Identifying cooperating modules of driver alterations can provide insights into cancer etiology and advance the development of effective personalized treatments. We present Cancer Rule Set Optimization (CRSO) for inferring the combinations of alterations that cooperate to drive tumor formation in individual patients. Application to 19 TCGA cancer types revealed a mean of 11 core driver combinations per cancer, comprising 2-6 alterations per combination and accounting for a mean of 70% of samples per cancer type. CRSO is distinct from methods based on statistical co-occurrence, which we demonstrate is a suboptimal criterion for investigating driver cooperation. CRSO identified well-studied driver combinations that were not detected by other approaches and nominated novel combinations that correlate with clinical outcomes in multiple cancer types. Novel synergies were identified in NRAS-mutant melanomas that may be therapeutically relevant. Core driver combinations involving NFE2L2 mutations were identified in four cancer types, supporting the therapeutic potential of NRF2 pathway inhibition. CRSO is available at .
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据